UN
RELENTING
Our serial innovation approach to CAR T cell development means that each new generation builds on previous discoveries, resulting in iterative advancements in safety and efficacy.
Our serial innovation approach to CAR T cell development means that each new generation builds on previous discoveries, resulting in iterative advancements in safety and efficacy.
PSMA is found in all prostate tissue; however, its levels progressively increase with disease stage and are typically highest among patients with aggressive, advanced stage castration-resistant prostate cancer.
Our proprietary, PSMA-specific binders allow our CAR T Cells to effectively target prostate cancer cells. Following successful proof of concept studies, the PSMA-01 and PSMA-02 CAR T Cells are being further evaluated in clinical trials.
TGF-β is an immunoinhibitory cytokine secreted by various tumors, including prostate cancer, and their microenvironment. We armor our CAR T Cells with dnTGF-βRII to block TGF-β signaling and protect them from its immunoinhibitory effects. Resulting CAR T Cells, such as PSMA-01 and PSMA-02, exhibit higher proliferation rates, improved persistence, and enhanced antitumor responses.
Targeting TnMUC1 has demonstrated proof of concept in ovarian, pancreatic, non-small cell lung, and triple-negative breast cancers.
*In collaboration with the Children’s Hospital of Philadelphia.
